BioSpace News Archive

Alphamab Oncology announced that Jiangsu Alphamab Biopharmaceuticals Co., Ltd., a wholly-owned subsidiary of the Company, has established strategic partnership with Simcere and 3D Medicines Co., Ltd. to advance the development and commercialization of KN035, a checkpoint inhibitor for programmed cell death ligand-1, for oncology indications in mainland China.

IMV Inc., a clinical-stage biopharmaceutical company, provided updates on the development of DPX-COVID-19, a vaccine candidate against the novel coronavirus, and on the Company’s business and clinical operations amid the COVID-19 pandemic.

Can-Fite BioPharma Ltd. announced it is implementing an interim analysis of the Phase III Comfort™ trial designed to evaluate the Company’s drug candidate, Piclidenoson, in the treatment of moderate-to-severe plaque psoriasis.

Humana, a national health care company, has announced it is waiving consumer costs for treatment related to COVID-19-covered services.

Multiple Clinical & Preclinical Candidates for Rare Cancers, Including a Novel Radiotherapeutic for Glioblastoma

Avenue Therapeutics, Inc., a company focused on the development of intravenous tramadol for the U.S. market, reported financial results and recent corporate highlights for the year ended December 31, 2019..

MediWound Ltd., a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, provided an update on certain impacts of the COVID-19 pandemic on its business operations and clinical programs.

Oyster Point Pharma, Inc. announced completion of enrollment in its pivotal Phase 3 ONSET-2 clinical trial of OC-01 nasal spray for the treatment of signs and symptoms of dry eye disease on March 14, 2020.

- Rimegepant 75 mg, dosed every other day, demonstrates statistically significant superiority, compared to placebo, on the primary endpoint of reduction in the mean number of migraine days per month - Orally administered rimegepant 75 mg, approved earlier this year for the acute treatment of migraine, is the only CGRP targeting therapy to demonstrate efficacy in both the acute and preventive treatment of migraine - Biohaven plans to engage the FDA and European

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2019 and provided a company update. “During the fourth quarter of 2019 and into early 2020, we made considerable progress against our longer-term strategic and operational objectives, particularly with our later-stage candidates Ovaprene ® , DARE-BV1, and Sildenafil Cream, 3.6%. This progress has helped pos